PerQseal Elite Vascular Closure Device
Vivasure Medical , Ltd. · Decision date Oct 16, 2026
What did the FDA approve?
FDA records P250015 as an original PMA application. The recorded decision is approval, dated Oct 16, 2026.
FDA approval order statement
Approval for the PerQSeal Elite Vascular Closure Device. The device is indicated for the percutaneous closure of common femoral arteriotomies in patients following interventional endovascular catheterization procedures utilizing 14 22 F sheaths (arteriotomies up to 26 F).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
Regulatory record facts
- Identifier
- P250015
- Regulatory pathway
- Premarket approval application
- Applicant
- Vivasure Medical , Ltd.
- Product code
- MGB
- Decision code
- APPR
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Vivasure Medical , Ltd.
- Product code
- MGB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250015 received
Application receipt date recorded by FDA.
P250015 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250015. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
VASCADE 5F Vascular Closure SystemP120016/S043 | Cardiva Medical, Inc. | PMA supplement | Sep 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vivasure Medical , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Parkmore Business Park W., Galway, H91 V3KP
Sources and methodology
- Original FDA record: P250015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


